supported by the Key Project of the National Natural Science Foundation of China,No.81930070(to SF);the National Natural Science Foundation of China,No.81972074(to XY);the Key Program of Natural Science Foundation of Tianjin,No.19JCZDJC34900(to XY)。
Argatroban is a synthetic thrombin inhibitor approved by U.S.Food and Drug Administration for the treatment of thrombosis.However,whether it plays a role in the repair of spinal cord injury is unknown.In this study,we...
Objective: to explore the feasibility and effectiveness of butylphthalide sodium chloride combined with argatroban in the clinical treatment of patients with ischemic stroke. Methods: the study was conducted in a retr...
BACKGROUND Argatroban is a novel direct thrombin inhibitor that has been used for treatment of acute ischemic stroke(AIS).To our knowledge,no systematic analysis has assessed the efficacy and safety of argatroban for ...
Use of extracorporeal membrane oxygenation to support patients with critical cardiorespiratory illness is increasing.Systemic anticoagulation is an essential element in the care of extracorporeal membrane oxygenation ...
Objective: Analyze the effect of argatroban on neurological function in patients with acute cerebral infarction and explore its possible mechanisms. Methods: From August 2015 to August 2017, 140 patients with acute ce...
Forced degradation study of argatroban under conditions of hydrolysis(neutral, acidic and alkaline), oxidation,photolysis and thermal stress, as suggested in the ICH Q1 A(R2), was accomplished. The drug showed signifi...
Argatroban is an intravenous DTI (direct synthetic thrombin inhibitor) that is not routinely used for anticoagulation; thus, expertise surrounding its use is very limited. Therefore, this case reviews an unusually h...
Sustained accumulation of 111 Indiumlabelled platelets is induced in the cerebral vasculature of rabbits by bolus intracarotid (i.c.) administration of thrombin. Bolus i.c. injection of the thrombin inhibitor Argatrob...